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Abstract: Central venous catheters are an invaluable tool for diagnostic and therapeutic 
  purposes in today’s medicine, but their use can be complicated by bloodstream infections (BSIs). 
While evidence-based preventive measures are disseminated by infection control associations, 
the optimal management of established central line-associated BSIs has been summarized in 
infectious diseases guidelines. We prepared an overview of the state-of-the-art of prevention and 
management of central line-associated BSIs and included topics such as the role of antibiotic-
coated catheters, the role of catheter removal in the management, and a review of currently used 
antibiotic compounds and the duration of treatment.
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Introduction
Central venous catheters (CVCs) are indispensable in medical care today. They are 
used for monitoring the hemodynamic status, for performing hemodialysis, and for 
administering medications, fluids, blood products, and total parenteral nutrition. 
In the United States, more than 150 million intravascular devices are sold each year.1 
Intravascular devices are available in different types based on their purposes and the 
anticipated duration of catheterization and can be classified into short-term versus 
long-term catheters, with the latter requiring surgery for insertion. Although, mostly 
encountered in intensive-care units (ICUs), CVCs are increasingly used in non-ICU 
wards2 and outpatient settings. However, rates of CVC use are much higher in ICUs 
than in other settings, and the associated morbidity is greatest in the critically ill 
patient population.
Owing to the invasive procedure necessary for placing a CVC and the remaining 
break in the integument, complications such as exit-site infections and bloodstream 
infections (BSIs) can develop. Pathogens either migrate along the outer surface of the 
catheter into deeper tissue and the bloodstream, or, less commonly, they are introduced 
into the catheter hub and proceed along the lumen. CVC-associated BSIs or central line-
associated bloodstream infections (CLABSIs) are among the most frequent health care-
associated infections. The infection risk varies with a number of factors, eg, the type 
of device,3 the insertion site,4 and the adherence to preventive measures.5 In situations 
of unknown risk factors, root cause analyses have been helpful and are recommended 
by national associations such as APIC (http://www.apic.org/Content/NavigationMenu/
PracticeGuidance/APICEliminationGuides/CRBSI_Elimination_Guide_logo.pdf). 
It also appears that the infection risk is not linear along the catheter age but increases Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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over time. It is estimated that 250,000 episodes of CLABSI 
occur in the United States each year, with an attributable 
mortality of 12%–25%.6 In addition, CLABSIs are known to 
increase the length of hospital stays as well as hospital costs. 
Hematogenous complications that may arise from CLABSI 
include endocarditis and osteomyelitis.
Incidence rates of catheter infections are usually presented 
as number of infections per 1000 catheter-days. The manual 
collection of data for this denominator is relatively time-
consuming; therefore, electronic algorithms have been studied 
with the goal of facilitating surveillance.7 Reported rates range 
from ,1 BSIs/1000 catheter-days8 to ∼10 and more9 but have 
been shown to decrease to 0 after interventions.10 The micro-
bial spectrum includes a variety of   Gram-positive and Gram-
negative bacteria as well as yeasts, with the predominant 
organisms being Staphylococcus aureus, coagulase-negative 
Staphylococci (CNS), and   Candida species (spp.). Catheter 
colonization with skin organisms can occur without producing 
any clinical symptoms.
Physical findings alone do not make for reliable diagnosis 
of a CLABSI. In the clinical setting, a CLABSI is commonly 
diagnosed by positive blood culture(s) and the absence of 
an apparent focus of infection other than the catheter. The 
CDC surveillance definition of a laboratory-confirmed BSI 
requires a positive blood culture in a patient where the recov-
ered organism cannot be related to an infection at another 
site;11 if a CVC has been in place at the time of the BSI or 
within the previous 48 hours, a CLABSI can be diagnosed. 
Importantly, no minimum of required catheter retention time 
has been formulated as part of this definition (see http://
www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScur-
rent.pdf).
Blood cultures should be obtained from both the catheter 
and peripherally prior to starting antibiotics, and following 
adequate skin preparation. Growth of S. aureus, CNS, and 
Candida spp. in blood cultures should raise the suspicion of 
CLABSI. Common skin contaminants are more difficult to 
interpret. If symptoms improve after removal of a catheter, 
even without any microbiological diagnosis, this is also sug-
gestive for a CLABSI. For suspected exit-site infections with 
drainage, an exit-site culture should be obtained.
Diagnostic approaches (along with laboratory criteria for 
diagnosis) are dependent on the capacity of the individual lab 
and can be classified based on whether the catheter is removed 
or retained. They include the semiquantitative method 
propagated by Maki et al, in which the catheter in question 
is removed and its tip rolled over an agar plate   (‘roll-plate 
method’).12 This method requires .15 colony-forming units 
(CFU) from the catheter tip and the same   organism growing 
from blood cultures; it exhibits high sensitivity and specific-
ity. Another method involves luminal flushing or sonication 
in order to obtain quantitative data. A cutoff or 1000 CFU 
has been shown to be indicative of infection, particularly in 
long-term catheters. However, both of the above methods 
require removal of the catheter and should only be used 
if a CLABSI is highly suspected. One of the methods not 
requiring catheter removal is to draw blood simultaneously 
through the catheter in question as well as peripherally and 
to compare colony counts. (CFU are required to be 3–5 
times as high in catheter blood cultures than in peripher-
ally obtained blood cultures in order to make a diagnosis 
of CLABSI).13 In the cited meta-analysis by Safdar et al, 
this method turned out to be the most reliable diagnostic 
approach. Also, catheter-drawn quantitative cultures can be 
obtained (with a cutoff of 100 CFU/mL) and in contrast, 
they appear to be the most cost-effective approach.14 A third 
approach measures the differential time until blood cultures 
turn positive; if the catheter blood culture turns positive at 
least 2 hours before the peripheral blood culture does, this 
argues in favor of a catheter   infection.15 Qualitative methods 
are not recommended.1
In this review, we summarize and discuss aspects of pre-
vention and management of CLABSIs. Detailed guidelines 
on both prevention and management have been published 
recently and should be consulted for further guidance.1,16
Prevention of central line-associated 
bloodstream infections
The Society for Healthcare Epidemiology of America (SHEA) 
and the Infectious Diseases Society of America (IDSA) have 
recently published guidelines compiling evidence-based 
approaches to prevent health care-associated infections in 
acute care hospitals and, more specifically, CLABSI.16,17 
These updated guidelines serve in concert with pre-existing 
guidance provided by the Healthcare Infection Control Prac-
tices Advisory Committee (HICPAC) as a basis for framing a 
discussion of current CLABSI prevention strategies.18
Prior to catheter insertion
education
Education remains the cornerstone of prevention of CLABSI 
and other nosocomial infections.19 In a prospective pre–post 
observational trial involving medical students and resident 
physicians, a 1-day instructional course on infection control 
emphasized the importance of using a full-size sterile drape as 
part of aseptic technique when placing a CVC. As a result,20 Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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documented use of full-size drapes increased from 44% to 
65% (P , 0.001), while CLABSI rates decreased from 3.3 
to 2.4 infections/1000 catheter-days. Another educational 
program consisting of a self-study module, staff in-service 
lectures, and the placement of fact sheets and posters through-
out the intervention unit to reinforce key infection-prevention 
concepts was directed toward physicians and nurses in 
a tertiary teaching hospital. CLABSI rates dropped sig-
nificantly after the program was introduced in the   medical21 
and surgical ICU22 of that hospital as well as in the ICU of 
an affiliated nonteaching community medical center.22,23 
A subsequent, multicenter observational study further vali-
dated this strategy, leading to a reduction in CLABSI rates 
from 11.2 to 8.9 infections/1000 catheter-days in the ICUs 
of six academic medical centers (risk ratio [RR] 0.79; 95% 
confidence intervals [CI]: 0.67–0.93).24 The use of hands-on, 
simulation-based training in proper CVC insertion as a 
supplement to didactic lectures also contributes to lowering 
CLABSI rates.20,25 Educational programs should be coupled 
with a formal credentialing process on an institutional basis 
to ensure the procedural competency of health care workers 
charged with placing CVCs. Periodic reassessment of health 
care worker knowledge regarding infection-prevention prac-
tices should be instituted to promote continued adherence to 
evidence-based practices.
At the time of catheter insertion
Hand hygiene
Hand hygiene remains a key measure in reducing nosocomial 
infections in the health care setting.26 Health care workers’ 
hands are frequently contaminated by organisms acquired 
from colonized patients and their immediate environment, 
and these may be readily transmitted to other patients in the 
absence of adequate hand hygiene.27 A relationship between 
proper hand hygiene and decreased nosocomial infections 
and cross-transmission has been established in several stud-
ies over the last 30 years.28 A comprehensive hand hygiene 
promotion program in Switzerland not only improved 
  compliance but also reduced nosocomial infections from a 
baseline prevalence of 16.9% to 9.9% (P = 0.04) in 4 years.29 
For the most part, the specific impact of improved hand 
hygiene on CLABSI has been measured as part of compre-
hensive infection-prevention strategies. In patients receiving 
parenteral nutrition, hand hygiene reduced CLABSI rates by 
72% (odds ratio [OR] 0.28; 95% CI: 0.09–0.88).30 After insti-
tution of an educational and performance feedback program 
to improve hand hygiene compliance in the ICU, a hospital in 
Argentina reported a dramatic increase in compliance from 
23% to 65% with a concomitant drop in overall nosocomial 
infection from 48 to 28/1000 patient-days (RR 0.59; 95% 
CI: 0.46–0.74; P , 0.0001).31 In a prospective interventional 
cohort study targeting instruction of proper hand hygiene and 
catheter care, compliance with hand hygiene improved only 
slightly from 59% to 65%.32 However, correct performance 
of hand hygiene increased from 23% to 43% (P = 0.003) 
and CLABSI rates decreased from 3.9 to 1.0/1000 catheter-
days after the intervention (P , 0.001). Hand hygiene with 
either an alcohol-based waterless product or antiseptic soap 
and water is mandated prior to CVC placement regardless 
of the fact that sterile gloves will be donned during the 
procedure.
Sterile precautions
Protective sterile barriers and clothing help minimize the 
risk of contamination and colonization of the catheter and 
insertion site during CVC placement. The benefit of maximal 
sterile barrier precautions (MSBPs), consisting of a surgical 
gown, sterile gloves, mask, cap, and a large sheet drape, in 
limiting CLABSI was initially borne out in a single-center 
randomized, controlled trial involving cancer outpatients 
receiving chemotherapy.33 CLABSI rates were sixfold higher 
in the control group which used only sterile gloves and a 
small drape (standard sterile barrier precautions, SSBP) dur-
ing catheter placement when compared to the intervention 
group assigned to use MSBP (0.5 versus 0.08 infections/1000 
catheter-days for the control versus the intervention group, 
respectively; P = 0.02). In a later prospective observational 
study, proper implementation of MSBP during CVC place-
ment reduced CLABSI rates in patients receiving paren-
teral nutrition by 74% (OR 0.26; 95% CI: 0.08–0.93).30 
Interestingly, a recent, multicenter randomized, controlled 
trial involving general surgery inpatients in Japan found no 
significant difference in CLABSI rates between SSBP and 
MSBP during CVC insertion (RR 0.84; 95% CI: 0.26–2.7; 
P = 0.77).34 The investigators, however, acknowledged that 
their study was underpowered to detect significant differ-
ences in CLABSI rates reported in the previous literature. 
MSBPs should be used throughout the entire procedure of 
CVC placement.
Skin antisepsis
Skin preparation with an antiseptic decreases the burden of 
skin flora at the site of catheter insertion. In a randomized, 
controlled trial comparing 10% povidone–iodine, 70% 
  alcohol, and 2% aqueous chlorhexidine for disinfection of 
central venous and arterial catheter sites in surgical ICU Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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patients at the time of insertion and with subsequent daily 
catheter site care, chlorhexidine was associated with the 
lowest incidence of CLABSI.35 In 2002, a meta-analysis 
of eight randomized, controlled trials revealed a summary 
RR for CLABSI of 0.49 (95% CI: 0.28–0.88) in patients 
whose catheter sites were disinfected with chlorhexidine 
when compared to povidone–iodine.36 Subsequent inves-
tigations have supported the superiority of chlorhexidine 
in the prevention of CLABSIs.37 Chlorhexidine has been 
demonstrated to affect a greater reduction in skin flora for 
a longer period of time than povidone–iodine and is not 
inactivated by blood or serum proteins.38 Current guidelines 
recommend that an alcohol-based chlorhexidine solution with 
a minimum chlorhexidine gluconate concentration of 0.5% 
be applied to the skin surface and allowed to dry prior to 
catheter insertion.16,18 Chlorhexidine skin preparations are not 
approved by the US Food and Drug Administration (FDA) 
for use in children younger than 2 months of age. In these 
patients,   povidone–iodine should be used instead.
Location of catheter
Use of the femoral vein for central venous access has been 
associated with greater rates of CLABSI. A prospective 
observational study of medical-surgical ward patients in a 
Veteran Affairs hospital identified an association between 
catheter colonization and femoral CVC placement (hazard 
ratio [HR] 4.2; 95% CI: 2.0–8.8; P = 0.0001).39 A multi-
center, randomized, controlled trial involving eight ICUs in 
France later demonstrated an association between femoral 
catheterization and increased infectious and thrombotic 
complications when compared to the subclavian approach 
(HR 4.83; 95% CI: 1.96–11.93, P , 0.001).4 A subsequent 
prospective observational study, also in critically ill patients, 
showed that the incidence density of CLABSI was signifi-
cantly higher for femoral (8.34) than for either jugular (2.99) 
or subclavian (0.97) approaches.40 In a subgroup analysis 
of femoral catheterizations for short-term dialysis access in 
critically ill patients, a body mass index .28.4 was found 
to be associated with an even higher risk of infection.41 
When the option exists, the current evidence supports either 
a jugular or subclavian approach for CVC placement, with 
some studies favoring the latter.40,42,43 In inpatients, the use 
of peripherally inserted central venous catheters (PICC) has 
emerged as an alternative to conventional CVCs in those 
requiring intermediate- to long-term vascular access, given 
their lower insertion complication rates. Yet, a prospective 
cohort study of ICU patients with PICCs yielded CLABSI 
rates similar to that of internal jugular and subclavian CVCs 
placed using the conventional approach.44 Therefore, the 
risk of CLABSI is not necessarily attenuated by the use of a 
PICC in every setting.
Systems-based intervention
Systems-based interventions promote greater adherence to 
the best practices described above. Use of a dedicated cart 
or kit standardizes CVC placement procedures and improves 
compliance with sterile technique. At one hospital, a routinely 
used standard CVC kit contained a small sterile drape and 
10% povidone–iodine antiseptic.45 This kit was replaced 
with a customized kit containing a large sterile drape and 
2% chlorhexidine gluconate in 70% isopropyl alcohol, which 
correlated with a decrease in CLABSI rates. The use of a 
universal catheter checklist not only prompts compliance 
but also ensures proper documentation of the utilization of 
infection-prevention strategies (Figure 1). A nurse, physician, 
or other trained health care professional should be appointed 
to observe the insertion of the CVC, review the checklist, 
monitor sterile technique, and should be empowered to 
  terminate the procedure if breaches are identified.
Several single-center studies have demonstrated the 
positive impact on CLABSI rates when comprehensive 
infection-prevention strategies, integrating education, and 
evidence-based guidelines are implemented.46,47 A collabora-
tive cohort of 103 ICUs across Michigan saw reduction in 
CLABSI rates by up to 66% over an 18-month period after 
a multifaceted intervention targeted hand hygiene, maximal 
barrier sterile precautions, chlorhexidine skin preparation, 
avoidance of the femoral site when possible, and removal of 
unnecessary catheters.10 A central line cart was stocked with 
the necessary supplies, and a checklist was used to document 
adherence. In nonemergency situations, CVC placement was 
stopped if sterile technique was breached. ICU teams received 
regular feedback regarding CLABSI rates. At 3 months 
after implementation of this quality improvement program, 
the median rate of CLABSI had decreased from a preinter-
vention baseline of 2.7 to 0 infections/1000 catheter-days 
(P # 0.002). CLABSI rates decreased from 7.7 at baseline 
to 1.4 between 16 and 18 months of follow-up (P , 0.002) 
with a sustained reduction in CLABSI rates of up to 66%. 
CLABSI incidence rate ratios decreased from 0.62 (95% CI: 
0.47–0.81) at 0–3 months after initiation of the intervention 
to 0.34 (95% CI: 0.23–0.50) at 16–18 months of follow-up. 
These reductions were sustained at 36 months of follow-up 
beyond the initial intervention.5 Similar successes were 
demonstrated in a cohort of 69 ICUs across   southwestern 
Pennsylvania, where CLABSI rates declined from 4.3 to Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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1.4 infections/1000 catheter-days over a 4-year period after 
comparable interventions (P , 0.001).48 On the basis of the 
success of these trials, CLABSI prevention bundles have 
been developed to promote best practices and improve patient 
outcomes in diverse hospital settings.49,50
After catheter insertion
Catheter care
Chlorhexidine-impregnated sponge dressings have emerged 
as a means to decrease skin flora colonization at the catheter 
insertion site and the subsequent risk of infection after 
NOT a part of the patient’s Medical Record.
Return to the Infection Prevention department.
Line placed emergently
(Patient Label)
Vascular Catheter Insertion Checklist
Persons within sterile field must wear mask, cap, sterile gown and gloves.
Any person in room/area must, at minimum, wear a mask during line insertion.
Before the procedure:
Assess patient (e.g., history, time of last meal, previous chest x-rays,
coagulation tests, APTT, as applicable)
Clamps in place on all lumens
Inserter:
Room/Unit:
Date: Observer:
Type of Line & Site:
Each person present is required to identify, stop, correct and report
any break in aseptic technique before resuming the insertion procedure.
Obtained informed consent
Provide patient and/or family education
Perform Time Out (additional Universal Protocol documentation
required per facility)
Avoid use of femoral vein whenever possible
During the procedure:
Perform hand hygiene
Use full barrier precautions: wear mask, cap, sterile gown and
gloves and place full-body drape over patient
Apply CHG skin prep for 30 seconds using back and forth
scrubbing motion (scrub for 2 minutes if moist skin site), unless
contraindicated (note alternate prep used below)
Sterile field maintained throughout procedure
After the procedure:
Ensure guidewire present and intact
Catheter caps placed on all lumens
Document line placement in patient chart
Yes Yes, after
prompt
Exceptions
(must document below)
Document exceptions here:
10/05/09 BJC 9-8001-020 BJC HealthCare
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t Before the procedure:
Sign on door or curtain to prevent entry of nonessential persons
Assistant present before starting procedure
Patient in Trendelenberg position for subclavian or internal jugular
catheter placement, unless contraindicated
During the procedure:
Perform hand hygiene
Wear mask, cap, sterile gloves and gown within sterile field
Label all syringes on sterile field
Apply sterile dressing, unless contraindicated (note reason for
exception below); document date and time of site dressing
Figure 1 example of a central vascular catheter insertion checklist. Copyright © 2010, reproduced with permission from BJC Infection Prevention and epidemiology 
Consortium.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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CVC insertion. A meta-analysis of eight studies examining 
the impact of chlorhexidine-impregnated sponge dressings on 
vascular and epidural catheter infection demonstrated a sig-
nificant reduction in catheter and exit-site colonization with 
a possible trend toward decreased CLABSI rates.51 A large 
randomized, controlled trial consisting of 3778 catheter epi-
sodes was later carried out in seven ICUs in France to further 
evaluate this question. Use of chlorhexidine-impregnated 
sponge dressings resulted in lower rates of major catheter-
related infection (0.6 versus 1.4/1000 catheter-days; HR 0.39, 
95% CI: 0.17–0.93; P = 0.03) and CLABSI (0.4 infections 
versus 1.3/1000 catheter-days; HR 0.24, 95% CI: 0.09–0.65; 
P = 0.005) when compared to standard dressings, despite a 
low-baseline infection rate.52 Another randomized, controlled 
trial of cancer patients undergoing chemotherapy also found 
a decreased incidence of CLABSIs in patients who received 
a chlorhexidine-impregnated sponge dressing compared to 
a standard sterile dressing (6.3% versus 11.3%, respectively; 
RR 0.54, 95% CI: 0.31–0.94).53
Dressing changes for nontunneled CVC should be per-
formed every 5–7 days in the absence of visible soiling or a 
break in the seal of the dressing. A multicenter, randomized, 
controlled study involving bone marrow transplant patients 
with tunneled- and nontunneled catheters demonstrated no 
significant increase in local infection or colonization when 
dressing changes occurred at longer intervals.54 In a larger 
randomized, trial, catheter colonization rates were similar 
between catheters assigned to 3- and 7-day interval dressing 
changes indicating noninferiority for the latter approach.52 
Catheter site care with a chlorhexidine solution during dress-
ing changes is advised. Catheter hubs, needleless connectors, 
and injection ports should be disinfected with either chlo-
rhexidine or 70% alcohol prior to use to reduce the risk of 
contamination.55 Evidence has emerged demonstrating that 
some types of needleless connectors may be associated with 
increased CLABSI rates.56 Intravenous administration sets 
not used to infuse blood products or lipids may remain safely 
in place for up to 96 hours without an increased incidence 
of infection.57 Administration sets containing blood products 
and lipids should be changed every 24 hours.
In some cases, antimicrobial locks for patients requiring 
long-term hemodialysis catheters have been shown to reduce 
the risk of CLABSIs.58 The instillation of antimicrobial 
  solution (eg, gentamicin, cefotaxime, and   minocycline) at 
supraphysiologic concentrations into the catheter lumen 
between hemodialysis sessions is thought to prevent 
intraluminal colonization and biofilm formation. However, 
the potential for antibiotic resistance and systemic toxicity 
from inadvertent leakage of antimicrobial solution at the 
catheter tip present important considerations. The use of 
taurolidine-citrate locks has not been shown to reduce the 
incidence of bacteremia as expected.59 In general, antimicro-
bial locks should be reserved for special populations with a 
history of limited venous access, recurrent CLABSI, or who 
are at increased risk for adverse sequelae from a CLABSI. 
Antimicrobial lock therapy for treatment of CLABSI will 
be addressed in greater detail in the section on management 
of CLABSI.
Reassessing the need for a catheter
The need for continued central venous access should be 
reevaluated on a daily basis as part of a multidisciplinary 
approach to patient care.60 CVCs no longer required for medi-
cal care should be promptly discontinued to eliminate the 
risk of future CLABSI. The incorporation of these infection-
prevention practices into CVC maintenance bundles has 
proven beneficial in decreasing CLABSI rates beyond the 
time around initial catheter placement.61 Finally, an ongoing 
surveillance program to monitor CLABSI incidence (reported 
per 1000 catheter-days) should be implemented to facilitate 
evaluation and validation of preventive strategies.
Special considerations
Antibiotic-coated catheters
The use of CVCs impregnated with antiseptics (eg, 
  chlorhexidine/silver sulfadiazine) or antimicrobials (eg, 
minocycline/rifampin) remains controversial. Such coated 
catheters are thought to discourage microbial colonization 
and biofilm formation of the catheter lumen or exterior. 
A meta-analysis recently examined 38 randomized, controlled 
trials spanning from 1993 through 200762 comparing anti-
infective-treated with standard CVCs. Of these, 27 trials pro-
vided CLABSI rates and revealed an advantage to use treated 
CVCs (OR 0.49, 95% CI: 0.37–0.64). It was unclear whether 
this advantage would persist after effective infection control 
bundles developed over the same period became standard 
of care. A separate meta-analysis showed that minocycline/
rifampin CVCs were associated with greater reductions in 
colonization and CLABSI compared to first-generation chlo-
rhexidine/silver sulfadiazine CVCs.63 Both meta-analyses 
commented on the overall poor methodological quality of the 
existing literature and iterated the need for further research. 
The use of these catheters is recommended primarily in 
clinical settings where CLABSI rates remain high despite 
standard   preventive strategies.16 Use may also be   considered 
in patients with limited venous access and a   history of recur-Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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rent CLABSI. Finally, patients with prosthetic devices or 
biomaterials (eg, heart valve or aortic graft) who are at a 
higher risk for adverse sequelae (eg, endocarditis) from a 
CLABSI may also be benefited.
Management of central  
line-associated bloodstream 
infections
In confirmed or suspected CLABSI, management is multi-
faceted and encompasses the selection of an empiric anti-
biotic, the determination of whether the infected catheter 
should be removed, the narrowing of antibiotic spectrum 
once a pathogen has been isolated, and a number of other 
considerations.
empiric treatment for central  
line-associated bloodstream infections
Vancomycin is recommended for the empiric treatment of 
CLABSI as CNS are the most common causative micro-
organisms, and also because of an increased prevalence of 
MRSA in many geographic areas.64 However, in situations 
where the minimal inhibitory concentration (MIC) for 
vancomycin is $2 ug/mL, alternative agents such as dap-
tomycin should be used.65,66 Linezolid should not be used 
for empiric therapy due to increased mortality reported in 
recipients with negative blood cultures or Gram-negative 
bacteremia.67
Additional coverage for Gram-negative bacilli should be 
administered in patients with severe illness, sepsis, a femoral 
catheter in place, a known focus of Gram-negative bacterial 
infection, or immunocompromised states including neutro-
penia or malignancy.68,69 Empiric coverage for Gram-negative 
bacilli should be based on local antimicrobial susceptibil-
ity data; appropriate choices include a fourth-generation 
cephalosporin, a carbapenem, or a β-lactam/β-lactamase 
inhibitor combination, with or without an aminoglycoside. 
Dual empiric antibiotic coverage for suspected multidrug-
resistant (MDR) Gram-negative bacilli such as   Pseudomonas 
  aeruginosa can be used until susceptibility data are available 
and antibiotic therapy can be de-escalated.70 For critically 
ill patients with femoral catheters, Candida spp. should be 
covered in addition to bacterial pathogens.71 Empiric coverage 
for central line-associated candidemia should also be initiated 
in septic patients with any of the following risk factors: total 
parenteral nutrition, prolonged use of broad-spectrum antibi-
otics, hematologic malignancy, bone marrow or solid-organ 
transplant, or colonization with Candida spp. at multiple 
sites.1 An echinocandin (eg, anidulafungin, micafungin, or 
caspofungin) is the preferred antifungal agent for treatment 
of suspected central line-associated candidemia.72
The duration of therapy for CLABSI is dependent on the 
organism suspected or isolated as well as evidence for endo-
vascular sequelae. Treatment of an uncomplicated CLABSI 
due to Enterococcus or Gram-negative bacilli ranges from 
7 to 14 days, while S. aureus may require anywhere from 
2 to 4 weeks. Longer courses (4–6 weeks) are required in 
patients with fungemia or bacteremia that persists more than 
72 hours after initiating appropriate antibiotics and remov-
ing the infected catheter, as well as in patients with infective 
endocarditis or suppurative thrombophlebitis.1 A further 
discussion of pathogen-specific treatment and duration of 
therapy follows.
Catheter removal
Not all patients with vascular catheters in place and a docu-
mented BSI have CLABSI. A catheter does not need to be 
removed if the BSI was due to an unrelated infection, such 
as urinary tract infection or pneumonia. Diagnostic appro-
aches to CLABSI have been discussed in the introduction of 
this article and may help discern if a BSI should be managed 
as CLABSI or not. In the following paragraphs, we discuss 
whether an infected catheter should be removed after the 
diagnosis of CLABSI has been made.
Infected short-term catheters such as peripheral venous 
catheters, peripheral arterial catheters, midline catheters, and 
short-term, nontunneled CVCs should be removed.73
Long-term catheters such as PICCs, long-term tun-
neled CVCs, and implantable devices should be removed in 
patients with CLABSI with any of the following conditions: 
severe sepsis, suppurative thrombophlebitis, endocarditis, 
metastatic complications such as pulmonary embolism, 
peripheral embolism in the setting of arterial catheters, 
BSI that   continues .72 hours after appropriate antibiotic 
therapy, infection due to S. aureus, fungi, or mycobacte-
ria, or   tunnel or pocket infections.1 Catheters that are in 
place for ,2 weeks are often infected extraluminally and 
should be removed. Antibiotic lock therapy (discussed in 
detail below) is unlikely to be effective in the setting of 
an extraluminal infection74–77 and should be reserved for 
managing long-term catheter infections. Catheters infected 
by Gram-negative organisms should be removed as retained 
catheters have been associated with significantly higher rates 
of treatment failure and recurrence.78 However, recent studies 
have shown high success rates in the treatment of CLABSI 
caused by Gram-negative organisms combining systemic 
antibiotic and antibiotic lock therapy in selected patients.75,79 Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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For low-virulence organisms that are difficult to eradicate 
including Corynebacterium spp., Bacillus spp., Micrococ-
cus spp., and Propionibacterium, infected catheters should 
be removed after blood culture contamination is ruled out 
with multiple positive culture results (see Pathogen-specific 
treatment for detail). For CNS CLABSI, catheters may be 
retained and patients may be treated with systemic antibiotic 
and antibiotic lock therapy.1
In uncomplicated CLABSI involving long-term catheters, 
treatment can be attempted without catheter removal due 
to limited access sites in patients who require long-term 
intravascular access for survival.80,81 If a catheter is retained, 
antibiotic lock therapy along with systematic antibiotics is 
usually recommended for catheter salvage, and repeat blood 
cultures should be obtained 1 week after antibiotic treat-
ment.82 Catheter salvage with systematic antibiotics alone 
was attempted in selected hemodialysis patients with infected 
tunneled catheters with an initial success rate of 61%, but 
recurrence was higher in this group (33% versus 8%).83
Antibiotic lock therapy
Antibiotic concentrations must be 100–1000 times greater to 
kill sessile bacteria within a biofilm than to kill planktonic 
bacteria.84 Preparing supratherapeutic concentrations of anti-
biotics and allowing them to dwell intraluminally within an 
infected catheter for hours to days may facilitate eradication 
of intraluminal infections because systemic antibiotics cannot 
achieve therapeutic levels there. Antibiotic lock therapy is a 
promising approach but is not widely established and should 
not be used if catheter removal is easily feasible.
Antibiotic lock solutions containing the desired antibi-
otic solution can be mixed with normal saline or heparin 
to fill the catheter lumen (typically 2–5 mL). In general, 
lower concentrations of heparin (#1000 units/mL) result in 
antibiotic precipitation, whereas higher concentrations of 
heparin (3500–10,000 units/mL) are compatible with a wider 
range of antibiotic concentrations.85 The indwelling time 
for an antibiotic lock should not exceed 48 hours (no more 
than 24 hours in the case of a femoral catheter) as antibiotic 
concentrations decrease significantly thereafter.86
Commonly used antibiotic lock therapy solutions are listed 
in Table 1. Other than those listed, teicoplanin,81,87 linezolid,85 
levofloxacin,81 cefazolin,76 ampicillin,88 amoxicillin,89 and 
combined antibiotic lock therapy such as vancomycin + 
  gentamicin76 and cefazolin + gentamicin76 have been 
described in the literature.
Managing patients with hemodialysis 
catheter infection
Management of hemodialysis catheter infections is chal-
lenging not only because the diagnosis is difficult, but also 
because the catheter is both the source of the infection and 
at the same time required for providing ongoing dialysis. The 
diagnosis of catheter infection requires at least one blood 
culture from a peripheral vein; however, it is not always 
feasible to draw peripheral blood cultures from patients 
who are receiving hemodialysis. Peripheral venous access is 
frequently exhausted from multiple, failed grafts or fistulas. 
Phlebotomy sites are further limited when future creation 
of a graft or fistula in an extremity is anticipated. When a 
peripheral blood culture cannot be obtained, blood samples 
can be drawn from the dialysis tubing during hemodialysis 
because systemic blood is circulating extracorporeally.95 
An infected catheter should be removed immediately in 
patients with either of the following: severe sepsis, hemo-
dynamic instability, evidence of metastatic infection, signs 
of accompanying exit-site or tunnel infection, fever and/or 
bacteremia that persist 72 hours after initiation of antibiotics 
to which the organism is susceptible, and with infection due 
to difficult-to-cure pathogens such as S. aureus, Pseudomo-
nas, MDR bacterial pathogens, or Candida and other fungi.96 
A temporary catheter can be placed at a different anatomical 
site. A new permanent dialysis catheter can be placed after 
the BSI has cleared. When there is no alternative site for 
Table 1 Final concentrations of common antibiotic lock solutions
Antibiotic and dosage Heparin dosage References
vancomycin 2 mg/mL 10 units/mL Robinson et al88
Daptomycin 5 mg/mL 100–10,000 units/mL Carpenter and Chambers90
Gentamicin 1 mg/mLa 2500 units/mL Krishnasami et al76
Ciprofloxacin 0.2 mg/dL 5000 units/mL Droste et al85
Ceftazidime 0.5 mg/dL 100 units/mL Rijnders et al91
Piperacillin-tazobactam 10 mg/mL 100 units/mL Del Pozo et al81
ethanol 70% No Onland et al,92 Maiefski et al,93 
and Sanders et al94
Note: aHeparin partially inhibits the antimicrobial activity of gentamicin, but this inhibition was overcome in vitro by a gentamicin concentration of 1 mg/mL.76Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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a new catheter, catheter exchange through a guide wire can 
be attempted, preferably 3 days after appropriate and effec-
tive antibiotic treatment.82 Hemodialysis catheter infection 
can be managed with antibiotic lock therapy along with 
systemic antibiotics for patients without an indication for 
immediate catheter removal as mentioned above. If a catheter 
is retained, blood cultures should be checked 1 week after 
completion of antibiotic treatment. The catheter should be 
removed if the repeat culture remains positive.82 The success 
rate for catheter salvage varies among infecting organisms, 
with Gram-negative organisms other than Pseudomonas 
ranking highest (87%–100%), followed by Staphylococcus 
  epidermidis (75%–84%), and Enterococcus (61%).75,76,81
Empiric antibiotic therapy for hemodialysis catheter 
infection should consist of vancomycin for Gram-positive 
bacteria and a third-generation cephalosporin or an amino-
glycoside for Gram-negative coverage.97 Third-generation 
cephalosporins are preferred over aminoglycosides due 
to the substantial risk of irreversible aminoglycoside 
oto-/  vestibulotoxicity in dialysis patients.98 Vancomycin-
resistant Enterococcus can be treated with daptomycin 
administered after each dialysis session. Cefazolin is favored 
over vancomycin in patients with methicillin-sensitive 
S. aureus (MSSA) bacteremia.99 There are higher failure 
rates in treating MRSA bacteremia if the vancomycin MIC 
is $2 ug/mL;65 daptomycin should be considered in these 
cases.66 Antibiotics that can be dosed after each hemodialysis 
session are preferable, including vancomycin, ceftazidime, 
and cefazolin (see Table 2). Candidemia in dialysis patients 
is treated with echinocandins, amphotericin B, or fluconazole 
in conjunction with catheter removal.76
Hemodialysis patients with uncomplicated CLABSI 
can be treated with systemic antibiotics for 3 weeks.100 
Those with metastatic infection such as endocarditis, 
  suppurative   thrombophlebitis, or persistent bacteremia or 
fungemia .72 h after catheter removal and appropriate 
antibiotic therapy should receive 4–6 weeks of antibiot-
ics. Patients with secondary osteomyelitis should receive 
6–8 weeks of antibiotics.1
Pathogen-specific treatment
Staphylococcus aureus
S. aureus bacteremia is associated with a high rate of 
deep-seated metastatic infections. Patients with S. aureus 
CLABSI should undergo prompt catheter removal. Delay in 
catheter removal increases the risk of hematogenous com-
plications, such as septic arthritis, vertebral osteomyelitis, or 
endocarditis.74,75 Predictors of hematogenous complications 
include positive blood culture results 72 hours after initiation 
of appropriate antibiotics or catheter removal, community-
acquired infection, hemodialysis dependence, diabetes, and 
a higher mean APACHE II score.74 Transesophageal echocar-
diogram (TEE) should be performed in patients with persis-
tent fever or BSI .72 h after catheter withdrawal in addition 
to initiation of appropriate antibiotic therapy.1   Transthoracic 
echocardiogram (TTE) findings are insufficient to rule out 
infective endocarditis.101,102
S. aureus CLABSI is usually treated for 4–6 weeks. 
However, a 14-day course of antibiotics may be sufficient if 
a TEE has ruled out endocarditis for patients without any of 
the following risk factors for infective endocarditis or other 
deep tissue infection related to S. aureus bacteremia: diabe-
tes, immunosuppression, prosthetic intravascular devices, 
evidence of endocarditis or suppurative thrombophlebitis 
on TEE or ultrasound, retained infected catheters, persistent 
fever, or bacteremia .72 hours after appropriate antibiotic 
treatment.103,104
Oxacillin or nafcillin is the drug of choice for MSSA 
bacteremia, while vancomycin is the standard treatment for 
MRSA infection. There are higher failure rates in treating 
MRSA bacteremia if the vancomycin MIC is $2 ug/mL;65 
alternative therapy with daptomycin, linezolid, or telavancin 
should be considered in these cases.66 Daptomycin is a cyclic 
lipopeptide. It causes depolarization of the bacterial cell mem-
brane and is bactericidal. It is approved by the FDA for com-
plicated skin and soft tissue infections and bacteremia with/
without endocarditis due to MRSA or other   Gram-positive 
cocci.66,105 Linezolid is at least noninferior to vancomycin in 
patients with CLABSI caused by Gram-positive organisms.66 
However, prolonged use can cause significant side effects 
such as bone marrow suppression and peripheral neuropathy. 
Outbreaks of linezolid-resistant MRSA have been reported.106 
Table 2 Preferred antibiotics regimen commonly used in dialysis 
patients
Antibiotic Dosing
vancomycin 20 mg/kg loading dose during the last 
hour of the dialysis session, then 
500 mg during the last 30 min of 
each subsequent dialysis session
Gentamicin 1 mg/kg, not to exceed 100 mg, after 
each dialysis session
Ceftazidime 1 g after each dialysis session
Cefazolin 20 mg/kg after each dialysis session
Daptomycin 6 mg/kg after each dialysis session
echinocandins (caspofungin, 
micafungin, and anidulafungin), 
fluconazole, or amphotericin B
Dose and frequency are the same as 
in nondialysis patients (see Table 3)Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Linezolid, however, should not be used for empiric therapy 
due to increased mortality reported in recipients with negative 
culture results or Gram-negative bacteremia as mentioned 
before. Telavancin inhibits cell wall synthesis by binding to 
peptidoglycan chain precursors and produces bacterial mem-
brane depolarization. It is bactericidal against   Gram-positive 
cocci, including MRSA, vancomycin-intermittent S. aureus 
(VISA), vancomycin-resistant S. aureus (VRSA), and 
  daptomycin- or linezolid-resistant strains of MRSA.107 A pilot 
study comparing telavancin with standard therapy in patients 
with S. aureus bacteremia has been completed but the results 
remain forthcoming.
Coagulase-negative Staphylococci species
CNS are the most common cause of CLABSI.108 They are also 
the most common skin flora associated with blood culture 
contamination. The best indicator of a true CLABSI due to 
CNS is a high proportion of positive blood cultures performed 
on samples drawn from multiple sites including at least one 
from a peripheral vein.108 However, in a septic patient, even 
a single positive CNS blood culture should be considered 
clinically relevant. Untreated CNS bacteremia in this situa-
tion can lead to significant mortality.109 For uncomplicated 
CLABSI due to CNS, catheters can be salvaged with sys-
temic antibiotic and antibiotic lock therapy for 10–14 days. 
A shorter duration (5–7 days) of treatment may be acceptable 
if the infected catheter is removed.1
CLABSI due to S. lugdunensis can cause endocarditis and 
metastatic infections similar to those caused by S. aureus and 
should be managed in a manner similar to CLABSI due to 
S. aureus.110 However, S. lugdunensis is frequently suscep-
tible to a wider range of antibiotics than S. aureus.
Enterococcus species
Patients with CLABSI due to ampicillin-sensitive Enterococcus 
spp. should receive ampicillin as the first-line antibiotic therapy. 
Vancomycin can be used if the pathogen is resistant to ampicillin. 
Linezolid or daptomycin is used in vancomycin-resistant Entero-
coccus spp. The infected catheter should be removed when pos-
sible. If the catheter removal is not feasible due to coagulopathy or 
need for central venous access, antibiotic lock therapy combined 
with systemic antibiotics can be attempted, and combination 
therapy with an aminoglycoside is preferred.111
Gram-negative bacilli
Although Gram-positive organisms are the most common 
cause of CLABSI, Gram-negative organisms have been 
increasingly associated with BSIs.112 Multidrug resistance is 
a growing concern in Gram-negative bacteria. Enterobacte-
riaceae such as Escherichia coli and Klebsiella spp. can be 
extended-spectrum β-lactamase (ESBL) producers. ESBL-
producing organisms confer broad-spectrum resistance 
to third-generation cephalosporins, β-lactamase inhibitor 
combinations, and aztreonam. They may initially appear to 
be susceptible to these antibiotics and lead to inappropriate 
antibiotic selection and treatment failure.113 Carbapenems are 
the treatment of choice due to their superior activity against 
ESBL-producing organisms.114,115 However, the incidence of 
infections with carbapenem-resistant   Gram-negative bacteria 
is increasing, especially for Acinetobacter spp.116 Fortunately, 
sulbactam, polymyxin E (colistin), and aminoglycosides 
all have activity against Acinetobacter spp. Sulbactam is 
commercially available only in combination with ampicil-
lin. It is given in a fixed 2:1 ratio of ampicillin/sulbactam 
3 g q6h. Polymyxin E is given 2.5–5 mg/kg/day, divided by 
three times a day in patients with normal renal function.117 
Although tigecycline has activity against Acinetobacter spp., 
it achieves very low serum concentrations and is not recom-
mended for BSIs.
Controversy exists regarding whether combination 
therapy is necessary to treat P. aeruginosa infections assum-
ing a benefit of synergism. However, a meta-analysis that 
evaluated 64 randomized, trials comparing β-lactam mono-
therapy to a β-lactam in combination with an aminoglycoside 
failed to show a survival benefit.118 It seems reasonable to 
use combination therapy while antibiotic susceptibilities are 
pending in order to increase the likelihood that the organism 
is covered by at least one of the antibiotics used, especially 
in the case of suspected MDR P. aeruginosa.
Catheters infected with Gram-negative organisms 
should be removed because retained catheters have been 
associated with significantly higher rates of treatment fail-
ure and infection recurrence.69,78 However, recent studies 
have shown high success rates in treating CLABSI caused 
by Gram-negative organisms with systemic antibiotics and 
antibiotic lock therapy.75,79 In the case of Pseudomonas 
CLABSI, catheter removal is usually required,1,78 although 
treatment with systematic antibiotics in addition to anti-
biotic lock therapy has also shown success in selected 
cases.79 The duration of treatment should be 7–14 days 
if the infected catheter is removed, and 10–14 days if the 
catheter is retained.1
Candida species
Echinocandins are the preferred treatment in central line-
associated candidemia. For patients who cannot tolerate Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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echinocandins, liposomal amphotericin B is an alternative. 
Fluconazole can be considered if patients are not critically ill 
and if they have not had recent exposure to azoles. An echi-
nocandin is preferred in patients who have had recent azole 
exposure, whose illness is severe, or who is at high risk of 
infection with C. glabrata or C. krusei.72 C. krusei is intrinsi-
cally resistant to fluconazole and has variable sensitivity to 
voriconazole. C. glabrata is frequently resistant to the azoles. 
Echinocandins have excellent activity against C. glabrata 
and are the drug of choice. C. parapsilosis is susceptible to 
most antifungal agents; however, the MIC for C. parapsilosis 
for all echinocandins is higher than that of other Candida 
spp., and fluconazole is therefore the preferred antibiotic. 
Treatment for ∼14 days after the first negative blood culture 
is sufficient in uncomplicated candidemia without persis-
tent fungemia or metastatic complications.72 All patients 
with candidemia should undergo a dilated ophthalmologi-
cal evaluation to exclude Candida endophthalmitis after 
the candidemia is controlled and new spread to the eye is 
unlikely. Ophthalmological examination in neutropenic 
patients should be performed after recovery of neutrophil 
counts because neutropenic patients may not manifest visible 
signs of endophthalmitis before that.72
Infected catheters usually need be removed in CLABSI 
due to Candida spp.119,120 However, not all candidemia 
episodes are central line-associated. Raad et al evaluated 
404 cases of candidemia in patients with cancer and CVCs 
and found that catheter removal within 72 hours from the first 
positive blood culture was necessary for patients with central 
line-associated candidemia, but did not change the outcome 
when the candidemia was not associated with a central line.121 
The study found that most cases of candidemia were unlikely 
to be central line-associated and were either related to dis-
seminated candidiasis or to having received corticosteroids/
chemotherapy within the month before onset of candidemia.121 
One exception is C. parapsilosis, which is more frequently 
associated with catheters compared to other Candida spp.122 
Both echinocandins and liposomal amphotericin B penetrate 
well into Candida biofilms and exhibit similar MICs in bio-
films and in planktonic stage; however, resistance to flucon-
azole has been described in Candida biofilms even though 
Candida in planktonic form was fluconazole sensitive.123 
A recent analysis of 842 patients from two randomized, clini-
cal trials implied that early removal of a CVC within 48 hours 
of the detection of candidemia was not warranted in adults 
treated with an echinocandin or liposomal amphotericin B.124 
However, the authors did not distinguish between   CVC-related 
and -unrelated candidemia in their study.
Other Gram-positive microorganisms
Diagnosis of CLABSI due to Corynebacterium, Bacillus, and 
Micrococcus spp. requires at least two positive results of blood 
cultures performed on samples obtained from different sites. 
Commonly regarded as contaminants, isolation of these organ-
isms from a single blood culture set does not necessarily indi-
cate a true BSI.1 Catheters frequently need to be removed.125–127 
However, recent experience has shown a high success rate in 
catheter salvage with appropriate antimicrobial therapy.128,129 
The empiric antibiotic of choice is vancomycin. Therapy can 
be adjusted according to in vitro susceptibility for definitive 
treatment. If catheters are retained in Bacillus CLABSI, alter-
native antibiotics such as linezolid or carbapenems may be 
more effective than vancomycin.125 Ciprofloxacin is associated 
with recurrent infection in Micrococcus bacteremia and should 
be avoided even if in vitro susceptibility studies demonstrate 
sensitivity to this antibiotic (Table 3).127
Management of complications 
of CLABSI: suppurative 
thrombophlebitis and infective 
endocarditis
Suppurative thrombophlebitis and infective endocarditis 
must be considered in patients with persistent bacteremia 
or fungemia .72 hours of adequate antimicrobial therapy. 
Catheter removal is mandatory in both circumstances.
Patients with suppurative thrombophlebitis due to 
CLABSI should receive a minimum of 3–4 weeks of antimi-
crobial therapy. Whether heparin therapy should be included 
in the treatment of this condition remains controversial.135 
Surgical resection of the involved vein/thrombus is only 
indicated in patients with purulent superficial veins, patients 
in whom the infection extends beyond the vessel wall, or 
patients who have failed an antibiotic regimen.136
TEE to evaluate the possibility of an endocarditis should 
be performed in patients with CLABSI who have any of the 
following: a prosthetic heart valve, a pacemaker, an implant-
able defibrillator, persistent bacteremia/fungemia .72 hours 
of adequate antimicrobial therapy and catheter removal, or 
any case of S. aureus CLABSI in which a duration of therapy 
of ,4–6 weeks is considered.137–139 Current IDSA guidelines 
for treatment of endocarditis should be consulted.140
Conclusion
CLABSIs are among the most frequent health care-associated 
infections and cause significant morbidity and mortality as 
well as increased costs to the health care system. Preventive 
measures have been shown to lead to significant reduction of Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
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these infections, as exemplified by the bundling of a number 
of interventions in the landmark study by Pronovost et al.5 
The field of CLABSI prevention is evolving further, with the 
most recent development being the roll out of evidence-based 
strategies to multiple US states.141 There are, however, many 
topics that still deserve closer investigation, eg, what are the 
optimal precautions at time of catheter insertion, what is 
the role of maintenance checklists to ensure proper catheter 
site care, what infection risks are associated with specific 
needleless connectors, and what is the role of antibiotic lock 
solutions for prevention. The management of CLABSI, on the 
other hand, has been standardized by the recently updated, 
excellent IDSA guideline which gives detailed instructions 
for commonly encountered pathogens and management 
problems.1 In many cases, catheter removal is considered an 
essential part of the management; however, the data behind 
this are not equal in strength for all pathogens. Other topics 
that deserve further studies are can catheter removal alone 
without antibiotic treatment be a viable approach (specifi-
cally for CNS), what is the optimal time period after CLABSI 
before reinserting a new catheter, what is the optimal treat-
ment duration in retained catheters, do all S. aureus CLABSIs 
require an echocardiogram to define the treatment duration, 
and are follow-up blood cultures necessary after completing 
treatment. Although more and more evidence for the best 
practices in prevention and management of CLABSIs is 
accumulated, many questions remain to be elucidated.
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